Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis
Identifieur interne : 000237 ( Istex/Corpus ); précédent : 000236; suivant : 000238Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis
Auteurs : S. Verma ; S. A. Chong ; M. Subramaniam ; Y. H. ChanSource :
- Acta Psychiatrica Scandinavica [ 0001-690X ] ; 2002-09.
Abstract
Objectives To evaluate the effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis and to examine correlates of response in a naturalistic study.
Url:
DOI: 10.1034/j.1600-0447.106.s413.1_10.x
Links to Exploration step
ISTEX:5158AA7E4EB502008FCE50B335952A325AC7F9E1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><author><name sortKey="Verma, S" sort="Verma, S" uniqKey="Verma S" first="S." last="Verma">S. Verma</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Chong, S A" sort="Chong, S A" uniqKey="Chong S" first="S. A." last="Chong">S. A. Chong</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Subramaniam, M" sort="Subramaniam, M" uniqKey="Subramaniam M" first="M." last="Subramaniam">M. Subramaniam</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Chan, Y H" sort="Chan, Y H" uniqKey="Chan Y" first="Y. H." last="Chan">Y. H. Chan</name><affiliation><mods:affiliation>Clinical Trials and Epidemiological Research Unit, Singapore</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5158AA7E4EB502008FCE50B335952A325AC7F9E1</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1034/j.1600-0447.106.s413.1_10.x</idno><idno type="url">https://api.istex.fr/document/5158AA7E4EB502008FCE50B335952A325AC7F9E1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000237</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000237</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><author><name sortKey="Verma, S" sort="Verma, S" uniqKey="Verma S" first="S." last="Verma">S. Verma</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Chong, S A" sort="Chong, S A" uniqKey="Chong S" first="S. A." last="Chong">S. A. Chong</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Subramaniam, M" sort="Subramaniam, M" uniqKey="Subramaniam M" first="M." last="Subramaniam">M. Subramaniam</name><affiliation><mods:affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</mods:affiliation></affiliation></author><author><name sortKey="Chan, Y H" sort="Chan, Y H" uniqKey="Chan Y" first="Y. H." last="Chan">Y. H. Chan</name><affiliation><mods:affiliation>Clinical Trials and Epidemiological Research Unit, Singapore</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Psychiatrica Scandinavica</title><idno type="ISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><imprint><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="volume">106</biblScope><biblScope unit="supplement">s413</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="106">106</biblScope></imprint><idno type="ISSN">0001-690X</idno></series><idno type="istex">5158AA7E4EB502008FCE50B335952A325AC7F9E1</idno><idno type="DOI">10.1034/j.1600-0447.106.s413.1_10.x</idno><idno type="ArticleID">ACPSPO119_10</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-690X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objectives To evaluate the effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis and to examine correlates of response in a naturalistic study.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>S. Verma</name><affiliations><json:string>Woodbridge Hospital/Institute of Mental Health, Singapore,</json:string></affiliations></json:item><json:item><name>S. A. Chong</name><affiliations><json:string>Woodbridge Hospital/Institute of Mental Health, Singapore,</json:string></affiliations></json:item><json:item><name>M. Subramaniam</name><affiliations><json:string>Woodbridge Hospital/Institute of Mental Health, Singapore,</json:string></affiliations></json:item><json:item><name>Y. H. Chan</name><affiliations><json:string>Clinical Trials and Epidemiological Research Unit, Singapore</json:string></affiliations></json:item></author><articleId><json:string>ACPSPO119_10</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><qualityIndicators><score>5.3</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595 x 791 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractCharCount>183</abstractCharCount><pdfWordCount>31301</pdfWordCount><pdfCharCount>205599</pdfCharCount><pdfPageCount>38</pdfPageCount><abstractWordCount>25</abstractWordCount></qualityIndicators><title>Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><genre><json:string>abstract</json:string></genre><host><volume>106</volume><publisherId><json:string>ACPS</json:string></publisherId><pages><last>106</last><first>69</first></pages><issn><json:string>0001-690X</json:string></issn><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0447</json:string></eissn><title>Acta Psychiatrica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0447</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>psychiatry</json:string></scienceMetrix></categories><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1034/j.1600-0447.106.s413.1_10.x</json:string></doi><id>5158AA7E4EB502008FCE50B335952A325AC7F9E1</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/5158AA7E4EB502008FCE50B335952A325AC7F9E1/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/5158AA7E4EB502008FCE50B335952A325AC7F9E1/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5158AA7E4EB502008FCE50B335952A325AC7F9E1/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><author xml:id="author-1"><persName><forename type="first">S.</forename><surname>Verma</surname></persName><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation></author><author xml:id="author-2"><persName><forename type="first">S. A.</forename><surname>Chong</surname></persName><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation></author><author xml:id="author-3"><persName><forename type="first">M.</forename><surname>Subramaniam</surname></persName><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation></author><author xml:id="author-4"><persName><forename type="first">Y. H.</forename><surname>Chan</surname></persName><affiliation>Clinical Trials and Epidemiological Research Unit, Singapore</affiliation></author></analytic><monogr><title level="j">Acta Psychiatrica Scandinavica</title><idno type="pISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><idno type="DOI">10.1111/(ISSN)1600-0447</idno><imprint><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-09"></date><biblScope unit="volume">106</biblScope><biblScope unit="supplement">s413</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="106">106</biblScope></imprint></monogr><idno type="istex">5158AA7E4EB502008FCE50B335952A325AC7F9E1</idno><idno type="DOI">10.1034/j.1600-0447.106.s413.1_10.x</idno><idno type="ArticleID">ACPSPO119_10</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objectives To evaluate the effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis and to examine correlates of response in a naturalistic study.</p></abstract><abstract><p>Method Patients with first‐episode psychosis were evaluated at baseline and weekly for 6 weeks with the Positive and Negative Scale for Schizophrenia (PANSS), Simpson–Angus Rating Scale (SARS), Barnes Akathisia Rating Scale (BARS), Rating Scale for Side‐effects (RSSE), and the Abnormal Involuntary Movement Scale (AIMS).</p></abstract><abstract><p>Results 42 patients with a mean age of 24.85 ± 9.68 years and mean duration of untreated illness of 11.91 ± 22.04 months were recruited. The mean dose of risperidone was 1.82 ± 0.77 mg. The mean reduction in PANSS score was from 67.97 ± 20.02 at baseline to 42.53 ± 14.08 at week 6 (P < 0.005). The incidence of extrapyramidal symptoms was 9.5% and akathisia was 7.1%. 45.2% of patients showed more than or equal 40% reduction in the PANSS score (responders). When responders were compared to nonresponders, the responders had a significantly higher total and positive PANSS score at baseline.</p></abstract><abstract><p>Conclusion Risperidone is an effective and safe antipsychotic in first‐episode psychosis.</p></abstract></profileDesc><revisionDesc><change when="2002-09">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-12-13">References added</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-02-9">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/5158AA7E4EB502008FCE50B335952A325AC7F9E1/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell publishers</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0447</doi><issn type="print">0001-690X</issn><issn type="electronic">1600-0447</issn><idGroup><id type="product" value="ACPS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA PSYCHIATRICA SCANDINAVICA">Acta Psychiatrica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="09000"><doi origin="wiley">10.1111/acp.2002.106.issue-s413</doi><numberingGroup><numbering type="journalVolume" number="106">106</numbering><numbering type="supplement">s413</numbering></numberingGroup><coverDate startDate="2002-09">September 2002</coverDate></publicationMeta><publicationMeta level="unit" type="abstract" position="0006900" status="forIssue"><doi origin="wiley">10.1034/j.1600-0447.106.s413.1_10.x</doi><idGroup><id type="unit" value="ACPSPO119_10"></id></idGroup><titleGroup><title type="tocHeading1">Posters</title></titleGroup><eventGroup><event type="firstOnline" date="2008-07-18"></event><event type="publishedOnlineFinalForm" date="2008-07-18"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:Header result:Header" date="2010-03-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-01"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="69">69</numbering><numbering type="pageLast" number="106">106</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:ACPS.ACPSpo119_10.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="0"></count><count type="wordTotal" number="0"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title><title type="shortAuthors">Thursday, 26–Saturday, 28 September 2002</title><title type="short">3rd International Conference on Early Psychosis</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a9-26"><personName><givenNames>S.</givenNames><familyName>Verma</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a9-26"><personName><givenNames>S. A.</givenNames><familyName>Chong</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a9-26"><personName><givenNames>M.</givenNames><familyName>Subramaniam</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a9-27"><personName><givenNames>Y. H.</givenNames><familyName>Chan</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a9-26" countryCode="SG"><unparsedAffiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</unparsedAffiliation></affiliation><affiliation xml:id="a9-27" countryCode="SG"><unparsedAffiliation>Clinical Trials and Epidemiological Research Unit, Singapore</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Objectives </b> To evaluate the effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis and to examine correlates of response in a naturalistic study.</p><p><b>Method </b> Patients with first‐episode psychosis were evaluated at baseline and weekly for 6 weeks with the Positive and Negative Scale for Schizophrenia (PANSS), Simpson–Angus Rating Scale (SARS), Barnes Akathisia Rating Scale (BARS), Rating Scale for Side‐effects (RSSE), and the Abnormal Involuntary Movement Scale (AIMS).</p><p><b>Results </b> 42 patients with a mean age of 24.85 ± 9.68 years and mean duration of untreated illness of 11.91 ± 22.04 months were recruited. The mean dose of risperidone was 1.82 ± 0.77 mg. The mean reduction in PANSS score was from 67.97 ± 20.02 at baseline to 42.53 ± 14.08 at week 6 (<i>P</i> < 0.005). The incidence of extrapyramidal symptoms was 9.5% and akathisia was 7.1%. 45.2% of patients showed more than or equal 40% reduction in the PANSS score (responders). When responders were compared to nonresponders, the responders had a significantly higher total and positive PANSS score at baseline.</p><p><b>Conclusion </b> Risperidone is an effective and safe antipsychotic in first‐episode psychosis.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>3rd International Conference on Early Psychosis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Verma</namePart><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. A.</namePart><namePart type="family">Chong</namePart><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Subramaniam</namePart><affiliation>Woodbridge Hospital/Institute of Mental Health, Singapore,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y. H.</namePart><namePart type="family">Chan</namePart><affiliation>Clinical Trials and Epidemiological Research Unit, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract"></genre><originInfo><publisher>Blackwell publishers</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2002-09</dateIssued><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Objectives To evaluate the effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis and to examine correlates of response in a naturalistic study.</abstract><abstract>Method Patients with first‐episode psychosis were evaluated at baseline and weekly for 6 weeks with the Positive and Negative Scale for Schizophrenia (PANSS), Simpson–Angus Rating Scale (SARS), Barnes Akathisia Rating Scale (BARS), Rating Scale for Side‐effects (RSSE), and the Abnormal Involuntary Movement Scale (AIMS).</abstract><abstract>Results 42 patients with a mean age of 24.85 ± 9.68 years and mean duration of untreated illness of 11.91 ± 22.04 months were recruited. The mean dose of risperidone was 1.82 ± 0.77 mg. The mean reduction in PANSS score was from 67.97 ± 20.02 at baseline to 42.53 ± 14.08 at week 6 (P < 0.005). The incidence of extrapyramidal symptoms was 9.5% and akathisia was 7.1%. 45.2% of patients showed more than or equal 40% reduction in the PANSS score (responders). When responders were compared to nonresponders, the responders had a significantly higher total and positive PANSS score at baseline.</abstract><abstract>Conclusion Risperidone is an effective and safe antipsychotic in first‐episode psychosis.</abstract><relatedItem type="host"><titleInfo><title>Acta Psychiatrica Scandinavica</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0001-690X</identifier><identifier type="eISSN">1600-0447</identifier><identifier type="DOI">10.1111/(ISSN)1600-0447</identifier><identifier type="PublisherID">ACPS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s413</number></detail><extent unit="pages"><start>69</start><end>106</end></extent></part></relatedItem><identifier type="istex">5158AA7E4EB502008FCE50B335952A325AC7F9E1</identifier><identifier type="DOI">10.1034/j.1600-0447.106.s413.1_10.x</identifier><identifier type="ArticleID">ACPSPO119_10</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell publishers</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000237 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000237 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5158AA7E4EB502008FCE50B335952A325AC7F9E1
|texte= Effectiveness and tolerability of risperidone in Asian patients with first‐episode psychosis
}}
| This area was generated with Dilib version V0.6.29. |  |